US11618737B2 - Hydrolysis method for tert-butyl ester in gadolinium-based contrast agent - Google Patents

Hydrolysis method for tert-butyl ester in gadolinium-based contrast agent Download PDF

Info

Publication number
US11618737B2
US11618737B2 US16/761,178 US201916761178A US11618737B2 US 11618737 B2 US11618737 B2 US 11618737B2 US 201916761178 A US201916761178 A US 201916761178A US 11618737 B2 US11618737 B2 US 11618737B2
Authority
US
United States
Prior art keywords
tert
butyl ester
gadolinium
contrast agent
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/761,178
Other versions
US20210179568A1 (en
Inventor
Zhihua Zhang
Yunlong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hubei Tianshu Pharmaceutical Co Ltd
Original Assignee
Hubei Tianshu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubei Tianshu Pharmaceutical Co Ltd filed Critical Hubei Tianshu Pharmaceutical Co Ltd
Assigned to HUBEI TIANSHU PHARMACEUTICAL CO., LTD reassignment HUBEI TIANSHU PHARMACEUTICAL CO., LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIU, YUNLONG, ZHANG, ZHIHUA
Publication of US20210179568A1 publication Critical patent/US20210179568A1/en
Application granted granted Critical
Publication of US11618737B2 publication Critical patent/US11618737B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B01J21/063—Titanium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B01J21/066—Zirconium or hafnium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B01J21/08—Silica
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/08—Halides
    • B01J27/10—Chlorides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/135—Halogens; Compounds thereof with titanium, zirconium, hafnium, germanium, tin or lead
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/06—Washing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/08—Heat treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Definitions

  • the present disclosure relates to the technical field of contrast agents for diagnostic imaging, and more particularly, to a hydrolysis method for the tert-butyl ester in a gadolinium-based contrast agent.
  • NMRI Nuclear Magnetic Resonance Imaging
  • MRI Magnetic Resonance Imaging
  • the contrast agent can change the relaxation time of the surrounding water protons, increase the magnetic resonance contrast between the detection target site and the surrounding background tissue, and improve the sensitivity and accuracy of NMRI.
  • gadolinium-centered-complex-based targeting magnetic resonance technology has been most widely used in clinic.
  • the outer layer of gadolinium (Gd) has 7 unpaired electrons, so it is a powerful paramagnetic ion.
  • Non-complexed gadolinium ions are toxic, but the toxic effect of gadolinium can be almost completely eliminated without significantly affecting its paramagnetic effect after the gadolinium forms a complex with a non-toxic organic chelating agent.
  • Various chelating agents of gadolinium that can be injected intravenously have become an integral part of magnetic resonance imaging (MRI) technology, such as gadobutrol or gadoteridol.
  • MRI magnetic resonance imaging
  • gadolinium chelating agents A variety of preparation methods of gadolinium chelating agents have been described in the prior art. These preparation methods relate to a step of converting an ester containing a nitrogen atom into an acid. In this step, an acid is usually used to convert the ester into an acid. At the same time, a resin is used to separate the target product from impurities. This step makes the entire production process high in cost, low in yield, and low in purity of the target product in large-scale production.
  • a first purpose of the present disclosure is to provide a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent, comprising the step of hydrolyzing the tert-butyl ester with a catalyst, wherein the catalyst is prepared by a method comprising the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until solids are dissolved, adding silica to perform reaction for 1 to 5 h, filtering to obtain the solid, and washing and calcining the solid.
  • the molar ratio of the zirconia to titanium tetrachloride is 1:(0.1-1), preferably 1:(0.4-0.5).
  • the volume ratio of the sulfuric acid to water is (0.5-3):10, preferably (1-1.5):10.
  • the mass to volume ratio of the zirconia to silica is 1:(10-20), preferably 1:(12-15).
  • the calcination temperature is 500° C. to 700° C., preferably 550° C. to 600° C.
  • the tert-butyl ester is (s)-di-tert-butyl-2,2′-((2-((2-bis(2-(tert-butoxy)-2-oxoethyl)amino)-3-(4-ethoxyphenyl)propyl)(2-(tert-butoxy)-2-oxoethyl)amino)ethyl)aza)diacetate, or a compound having the structure shown in any one of the general formulae (I) to (III):
  • the mass ratio of the tert-butyl ester to the catalyst is 1:(1-1000), preferably 1:(50-100), and more preferably 1:100.
  • the hydrolysis temperature is 70° C. to 90° C., and the hydrolysis time is 8 to 24 h. More preferably, the hydrolysis temperature is 85° C. to 90° C., and the hydrolysis time is 12 to 15 h.
  • the weight ratio of the added water to the tert-butyl ester is 20:1 to 20:5.
  • the hydrolysis may specifically comprise: mixing the above-mentioned tert-butyl ester with water, adding the above catalyst to react at 70° C. to 90° C. for 8 to 24 h.
  • reaction solution may be filtered, washed with water, concentrated and then recrystallized using ethanol and/or acetone.
  • Another purpose of the present disclosure is to provide a catalyst for hydrolyzing tert-butyl ester in gadolinium-based contrast agent.
  • the preparation method of the catalyst comprises the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until solids are dissolved, adding silica to perform reaction for 1 to 5 h, filtering to obtain the solid, washing and calcining the solid.
  • the optimization of other conditions is as described in the related contents above, and is not repeated herein.
  • the hydrolysis method of the present disclosure does not introduce other substances that are difficult to remove, such as acids, and provides high hydrolysis efficiency and high purity of the obtained product (the purity is greater than 98%, and the yield is greater than 88%, more preferably, the purity is greater than 99%, and the yield is greater than 90%).
  • the production cost in the preparation process of the gadolinium-based contrast agent is greatly reduced, and the waste gas, waste water and waste residues produced in the preparation process are effectively reduced.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the reaction equation is as follows:
  • the hydrolysis method provided in the present Example comprises the following steps:
  • the compound represented by formula (III) was added into a 500 mL reaction flask containing 200 mL distilled water, and a catalyst was added under stirring (the mass ratio of the compound represented by formula (III) to the catalyst was 1:100) to perform reaction at 90° C. for 12 h, and then the resultant was filtered, washed with a small amount of water, concentrated to dry under reduced pressure, and recrystallized with 95% ethanol to obtain 17 g white solid of teridol.
  • the catalyst was prepared by the following method: 5 g ZrO 2 and 3 g TiCl 4 were added to 100 mL distilled water, and 10 mL sulfuric acid was added; the mixture was heated at about 80° C. until the solid were completely dissolved, and then 60 ml SiO 2 was added to perform adsorption for 2 h; and the resultant was filtered, washed twice with water, washed twice with 50 mL of 10% NaOH, and washed with distilled water to neutrality, and then calcined at 550° C. to obtain the catalyst.
  • the purity of the teridol obtained in the present Example is 99.8%, and the yield is 96%.
  • the elemental analysis results of the product obtained in the present Example are as follows: C: 50.37%, N: 13.80%, and H: 8.09%, C 17 H 32 N 4 O 7 theoretical values: C: 50.44%, N: 13.85%, and H: 8.01%; wherein, both the infrared spectrum and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example indicate that the obtained substance is teridol.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the reaction equation is as follows:
  • the purity of the butrol obtained in the present Example is 99.7%, and the yield is 95%.
  • the elemental analysis results of the product obtained in the present Example are as follows: C: 47.82%, N: 12.32%, and H: 7.64%, C 18 H 34 N 4 O 9 theoretical values: C: 47.97%, N: 12.43%, and H: 7.62%; wherein, both the infrared spectrum and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example indicate that the obtained substance is butrol.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the reaction equation is as follows:
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the reaction equation is as follows:
  • the hydrolysis method provided in the present Example comprises the following steps:
  • the compound represented by formula (III) was added into a 500 mL reaction flask containing 200 mL distilled water, and a catalyst was added under stirring (the mass ratio of the compound represented by formula (III) to the catalyst was 1:1) to perform reaction at 70° C. for 24 h, and then the resultant was filtered, washed with a small amount of water, concentrated to dry under reduced pressure, and recrystallized with 95% ethanol to obtain a white solid, wherein the catalyst used was the same as that used in Example 1.
  • the elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1.
  • the purity of the teridol obtained in the present Example is 99%, and the yield is 90%.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the reaction equation is as follows:
  • the hydrolysis method provided in the present Example comprises the following steps:
  • the compound represented by formula (III) was added into a 500 mL reaction flask containing 200 mL distilled water, and a catalyst was added under stirring (the mass ratio of the compound represented by formula (III) to the catalyst is 1:50) to perform reaction at 90° C. for 15 h, and then the resultant was filtered, washed with a small amount of water, concentrated to dry under reduced pressure, and recrystallized with 95% ethanol to obtain a white solid, wherein the catalyst used was the same as that used in Example 1.
  • the elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1.
  • the purity of the teridol obtained in the present Example is 99.5%, and the yield is 92%.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the reaction equation is as follows:
  • Example 5 The steps were the same as those in Example 5, except that the tert-butyl ester was a compound represented by formula (II); and the solvent for recrystallization was ethanol/acetone (6:4).
  • the purity of the butrol obtained in the present Example is 99.5%, and the yield is 93%.
  • the elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example are the same as those in Example 2.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the reaction equation is as follows:
  • Example 5 The steps were the same as those in Example 5, except that the tert-butyl ester was a compound represented by formula (I).
  • the purity of the product obtained in the present Example is 99%, and the yield is 90%.
  • the elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example are the same as those in Example 3.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the steps are the same as those in Example 1, except that the catalyst used in the present Example was prepared by the following method: 5 g ZrO 2 and 0.76 g TiCl 4 were added to 100 mL distilled water, and 5 mL sulfuric acid was added; the mixture was heated at about 80° C. until the solid was completely dissolved, 50 ml SiO 2 was added to perform adsorption for 2 h; and the resultant was filtered, washed twice with water, washed twice with 50 mL of 10% NaOH, and washed with distilled water to neutrality, and then calcined at 500° C. to obtain the catalyst.
  • the elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1.
  • the purity of the teridol obtained in the present Example is 99%, and the yield is 88%.
  • the present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the steps were the same as those in Example 1, except that the catalyst used in the present Example was prepared by the following method: 5 g ZrO 2 and 7.59 g TiCl 4 was added to 100 mL distilled water, and 30 mL sulfuric acid was added; the mixture was heated at about 80° C. until the solid was completely dissolved, 100 ml SiO 2 was added to perform adsorption for 2 h; and the resultant was filtered, washed twice with water, washed twice with 50 mL of 10% NaOH, and washed with distilled water to neutrality, and then calcined at 700° C. to obtain the catalyst.
  • the elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1.
  • the purity of the teridol obtained in the present Example is 98.5%, and the yield is 90%.
  • the present disclosure provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent.
  • the hydrolysis method includes the step of hydrolyzing the tert-butyl ester with a catalyst, wherein the the catalyst is prepared by a method including the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until the solids is dissolved, adding silica to perform reaction for 1 to 5 h, filtering to obtain the solid, washing and calcining the solid.
  • the hydrolysis method provided by the present disclosure can be used for industrial large-scale production, and makes up for the shortcomings of the existing method such as suitability for small-scale production only, insufficient purity, and low hydrolysis efficiency.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A hydrolysis method for tert-butyl ester in gadolinium-based contrast agent comprises hydrolyzing the tert-butyl ester with a catalyst. The preparation method of the catalyst comprises the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until solids are dissolved, adding silica to perform reaction for 1 to 5 h, filtering to obtain solids, washing and calcining the solids. This hydrolysis method does not introduce other substances that are difficult to remove, such as acids, and provides high hydrolysis efficiency and high purity of the obtained product.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase entry under 35 U.S.C. § 371 of International Patent Application PCT/CN2019/073688, filed Jan. 29, 2019, which claims the benefit under Article 8 of the Patent Cooperation Treaty to Chinese Patent Application Serial No. 2019100787560, filed Jan. 28, 2019.
TECHNICAL FIELD
The present disclosure relates to the technical field of contrast agents for diagnostic imaging, and more particularly, to a hydrolysis method for the tert-butyl ester in a gadolinium-based contrast agent.
BACKGROUND
Nuclear Magnetic Resonance Imaging (NMRI), also known as Magnetic Resonance Imaging (MRI), has become a conventional diagnostic technology in clinical medical diagnosis due to its advantages such as non-invasiveness, high-resolution anatomical imaging, and nontoxicity and harmlessness to living organisms. NMRI is based on the relaxation of water protons in the human body from high-energy hydrogen nuclei to low-energy nuclei under an external magnetic field to generate image. The image quality is affected by the density and distribution of water protons in the human body. In many cases, it is difficult to reach a clear Mill anatomy map, so it is difficult to accurately judge the disease and injury. The contrast agent can change the relaxation time of the surrounding water protons, increase the magnetic resonance contrast between the detection target site and the surrounding background tissue, and improve the sensitivity and accuracy of NMRI.
So far, gadolinium-centered-complex-based targeting magnetic resonance technology has been most widely used in clinic. The outer layer of gadolinium (Gd) has 7 unpaired electrons, so it is a powerful paramagnetic ion. Non-complexed gadolinium ions are toxic, but the toxic effect of gadolinium can be almost completely eliminated without significantly affecting its paramagnetic effect after the gadolinium forms a complex with a non-toxic organic chelating agent. Various chelating agents of gadolinium that can be injected intravenously have become an integral part of magnetic resonance imaging (MRI) technology, such as gadobutrol or gadoteridol.
A variety of preparation methods of gadolinium chelating agents have been described in the prior art. These preparation methods relate to a step of converting an ester containing a nitrogen atom into an acid. In this step, an acid is usually used to convert the ester into an acid. At the same time, a resin is used to separate the target product from impurities. This step makes the entire production process high in cost, low in yield, and low in purity of the target product in large-scale production.
BRIEF SUMMARY
A first purpose of the present disclosure is to provide a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent, comprising the step of hydrolyzing the tert-butyl ester with a catalyst, wherein the catalyst is prepared by a method comprising the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until solids are dissolved, adding silica to perform reaction for 1 to 5 h, filtering to obtain the solid, and washing and calcining the solid.
In a preferred embodiment of the present disclosure, the molar ratio of the zirconia to titanium tetrachloride is 1:(0.1-1), preferably 1:(0.4-0.5).
In a preferred embodiment of the present disclosure, the volume ratio of the sulfuric acid to water is (0.5-3):10, preferably (1-1.5):10.
In a preferred embodiment of the present disclosure, the mass to volume ratio of the zirconia to silica is 1:(10-20), preferably 1:(12-15).
In a preferred embodiment of the present disclosure, the calcination temperature is 500° C. to 700° C., preferably 550° C. to 600° C.
In a preferred embodiment of the present disclosure, the tert-butyl ester is (s)-di-tert-butyl-2,2′-((2-((2-bis(2-(tert-butoxy)-2-oxoethyl)amino)-3-(4-ethoxyphenyl)propyl)(2-(tert-butoxy)-2-oxoethyl)amino)ethyl)aza)diacetate, or a compound having the structure shown in any one of the general formulae (I) to (III):
Figure US11618737-20230404-C00001
In a preferred embodiment of the present disclosure, the mass ratio of the tert-butyl ester to the catalyst is 1:(1-1000), preferably 1:(50-100), and more preferably 1:100.
In a preferred embodiment of the present disclosure, the hydrolysis temperature is 70° C. to 90° C., and the hydrolysis time is 8 to 24 h. More preferably, the hydrolysis temperature is 85° C. to 90° C., and the hydrolysis time is 12 to 15 h.
In the above hydrolysis reaction, the weight ratio of the added water to the tert-butyl ester is 20:1 to 20:5.
In a preferred embodiment of the present disclosure, the hydrolysis may specifically comprise: mixing the above-mentioned tert-butyl ester with water, adding the above catalyst to react at 70° C. to 90° C. for 8 to 24 h.
After the end of the hydrolysis reaction, the reaction solution may be filtered, washed with water, concentrated and then recrystallized using ethanol and/or acetone.
Another purpose of the present disclosure is to provide a catalyst for hydrolyzing tert-butyl ester in gadolinium-based contrast agent. The preparation method of the catalyst comprises the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until solids are dissolved, adding silica to perform reaction for 1 to 5 h, filtering to obtain the solid, washing and calcining the solid. The optimization of other conditions is as described in the related contents above, and is not repeated herein.
The hydrolysis method of the present disclosure does not introduce other substances that are difficult to remove, such as acids, and provides high hydrolysis efficiency and high purity of the obtained product (the purity is greater than 98%, and the yield is greater than 88%, more preferably, the purity is greater than 99%, and the yield is greater than 90%). The production cost in the preparation process of the gadolinium-based contrast agent is greatly reduced, and the waste gas, waste water and waste residues produced in the preparation process are effectively reduced.
DETAILED DESCRIPTION
The specific embodiments of the present disclosure will be described in further detail in combination with the Examples below. The following Examples are used to illustrate the present disclosure, but not to limit the scope of the present disclosure.
Unless otherwise specified, the technical means used in the Examples are conventional means well known to a person skilled in the art, and the raw materials used are all commercially available products.
Example 1
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The reaction equation is as follows:
Figure US11618737-20230404-C00002
The hydrolysis method provided in the present Example comprises the following steps:
The compound represented by formula (III) was added into a 500 mL reaction flask containing 200 mL distilled water, and a catalyst was added under stirring (the mass ratio of the compound represented by formula (III) to the catalyst was 1:100) to perform reaction at 90° C. for 12 h, and then the resultant was filtered, washed with a small amount of water, concentrated to dry under reduced pressure, and recrystallized with 95% ethanol to obtain 17 g white solid of teridol.
Wherein, the catalyst was prepared by the following method: 5 g ZrO2 and 3 g TiCl4 were added to 100 mL distilled water, and 10 mL sulfuric acid was added; the mixture was heated at about 80° C. until the solid were completely dissolved, and then 60 ml SiO2 was added to perform adsorption for 2 h; and the resultant was filtered, washed twice with water, washed twice with 50 mL of 10% NaOH, and washed with distilled water to neutrality, and then calcined at 550° C. to obtain the catalyst.
The purity of the teridol obtained in the present Example is 99.8%, and the yield is 96%. The elemental analysis results of the product obtained in the present Example are as follows: C: 50.37%, N: 13.80%, and H: 8.09%, C17H32N4O7 theoretical values: C: 50.44%, N: 13.85%, and H: 8.01%; wherein, both the infrared spectrum and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example indicate that the obtained substance is teridol.
Example 2
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The reaction equation is as follows:
Figure US11618737-20230404-C00003
The steps were the same as those in Example 1, except that the tert-butyl ester was a compound represented by formula (II); and the solvent for recrystallization was ethanol/acetone (6:4). 21 g butrol was obtained in the present Example.
The purity of the butrol obtained in the present Example is 99.7%, and the yield is 95%. The elemental analysis results of the product obtained in the present Example are as follows: C: 47.82%, N: 12.32%, and H: 7.64%, C18H34N4O9 theoretical values: C: 47.97%, N: 12.43%, and H: 7.62%; wherein, both the infrared spectrum and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example indicate that the obtained substance is butrol.
Example 3
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The reaction equation is as follows:
Figure US11618737-20230404-C00004
The steps were the same as those in Example 1, except that the tert-butyl ester was a compound represented by formula (I).
The purity of the product obtained in the present Example is 99%, and the yield is 96%. 1H-NMR (400 MHZ) (DMSO-d6) δ: 1.31 (t (7 Hz), 2.47 (dd (14.7 Hz), 1H), 2.78-2.90 (m, 4H), 2.90-3.10 (m, 3H), 3.20-3.50 (m, 9H), 3.60-3.75 (m, 2H), 3.99 (q (7 Hz), 2H), 6.80-6.85 (m, 2H), 7.10-7.15 (m, 2H), 8-12 (m, 5H).
Example 4
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The reaction equation is as follows:
Figure US11618737-20230404-C00005
The hydrolysis method provided in the present Example comprises the following steps:
The compound represented by formula (III) was added into a 500 mL reaction flask containing 200 mL distilled water, and a catalyst was added under stirring (the mass ratio of the compound represented by formula (III) to the catalyst was 1:1) to perform reaction at 70° C. for 24 h, and then the resultant was filtered, washed with a small amount of water, concentrated to dry under reduced pressure, and recrystallized with 95% ethanol to obtain a white solid, wherein the catalyst used was the same as that used in Example 1. The elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1. The purity of the teridol obtained in the present Example is 99%, and the yield is 90%.
Example 5
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The reaction equation is as follows:
Figure US11618737-20230404-C00006
The hydrolysis method provided in the present Example comprises the following steps:
The compound represented by formula (III) was added into a 500 mL reaction flask containing 200 mL distilled water, and a catalyst was added under stirring (the mass ratio of the compound represented by formula (III) to the catalyst is 1:50) to perform reaction at 90° C. for 15 h, and then the resultant was filtered, washed with a small amount of water, concentrated to dry under reduced pressure, and recrystallized with 95% ethanol to obtain a white solid, wherein the catalyst used was the same as that used in Example 1. The elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1. The purity of the teridol obtained in the present Example is 99.5%, and the yield is 92%.
Example 6
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The reaction equation is as follows:
Figure US11618737-20230404-C00007
The steps were the same as those in Example 5, except that the tert-butyl ester was a compound represented by formula (II); and the solvent for recrystallization was ethanol/acetone (6:4). The purity of the butrol obtained in the present Example is 99.5%, and the yield is 93%. The elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example are the same as those in Example 2.
Example 7
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The reaction equation is as follows:
Figure US11618737-20230404-C00008
The steps were the same as those in Example 5, except that the tert-butyl ester was a compound represented by formula (I). The purity of the product obtained in the present Example is 99%, and the yield is 90%. The elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the product obtained in the present Example are the same as those in Example 3.
Example 8
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The steps are the same as those in Example 1, except that the catalyst used in the present Example was prepared by the following method: 5 g ZrO2 and 0.76 g TiCl4 were added to 100 mL distilled water, and 5 mL sulfuric acid was added; the mixture was heated at about 80° C. until the solid was completely dissolved, 50 ml SiO2 was added to perform adsorption for 2 h; and the resultant was filtered, washed twice with water, washed twice with 50 mL of 10% NaOH, and washed with distilled water to neutrality, and then calcined at 500° C. to obtain the catalyst.
The elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1. The purity of the teridol obtained in the present Example is 99%, and the yield is 88%.
Example 9
The present Example provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The steps were the same as those in Example 1, except that the catalyst used in the present Example was prepared by the following method: 5 g ZrO2 and 7.59 g TiCl4 was added to 100 mL distilled water, and 30 mL sulfuric acid was added; the mixture was heated at about 80° C. until the solid was completely dissolved, 100 ml SiO2 was added to perform adsorption for 2 h; and the resultant was filtered, washed twice with water, washed twice with 50 mL of 10% NaOH, and washed with distilled water to neutrality, and then calcined at 700° C. to obtain the catalyst.
The elemental analysis results, the infrared spectrum, and the nuclear magnetic resonance hydrogen spectrum of the teridol obtained in the present Example are the same as those in Example 1. The purity of the teridol obtained in the present Example is 98.5%, and the yield is 90%.
Finally, the methods described in the embodiments are only preferred embodiments, and are not intended to limit the protection scope of the present disclosure. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present disclosure shall be included in the protection scope of the present disclosure.
INDUSTRIAL APPLICABILITY
The present disclosure provides a hydrolysis method for tert-butyl ester in gadolinium-based contrast agent. The hydrolysis method includes the step of hydrolyzing the tert-butyl ester with a catalyst, wherein the the catalyst is prepared by a method including the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until the solids is dissolved, adding silica to perform reaction for 1 to 5 h, filtering to obtain the solid, washing and calcining the solid. The hydrolysis method provided by the present disclosure can be used for industrial large-scale production, and makes up for the shortcomings of the existing method such as suitability for small-scale production only, insufficient purity, and low hydrolysis efficiency.

Claims (1)

What is claimed is:
1. A method for preparing a catalyst for hydrolyzing tert-butyl ester in gadolinium-based contrast agent, the method comprising the following steps: subjecting zirconia and titanium tetrachloride to reaction in the presence of sulfuric acid and water at 60° C. to 90° C. until solids are dissolved, adding silica, performing a reaction for 1 to 5 h, filtering to obtain solids, washing and calcining the solids.
US16/761,178 2019-01-28 2019-01-29 Hydrolysis method for tert-butyl ester in gadolinium-based contrast agent Active 2039-12-24 US11618737B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910078756.0A CN109851516B (en) 2019-01-28 2019-01-28 Hydrolysis method of tert-butyl ester in gadolinium-based contrast agent
CN2019100787560 2019-01-28
CN201910078756.0 2019-01-28
PCT/CN2019/073688 WO2020154891A1 (en) 2019-01-28 2019-01-29 Hydrolysis method of tert-butyl ester used in gadolinium contrast agent

Publications (2)

Publication Number Publication Date
US20210179568A1 US20210179568A1 (en) 2021-06-17
US11618737B2 true US11618737B2 (en) 2023-04-04

Family

ID=66896492

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/761,178 Active 2039-12-24 US11618737B2 (en) 2019-01-28 2019-01-29 Hydrolysis method for tert-butyl ester in gadolinium-based contrast agent

Country Status (7)

Country Link
US (1) US11618737B2 (en)
EP (1) EP3835286B1 (en)
JP (1) JP7128890B2 (en)
KR (1) KR20210045348A (en)
CN (1) CN109851516B (en)
ES (1) ES2942312T3 (en)
WO (1) WO2020154891A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791089A (en) * 1983-10-07 1988-12-13 Enron Chemical Corporation Zirconia-titania-silica tergels and their use as catalyst supports
CN103068790A (en) 2010-06-11 2013-04-24 拜耳知识产权有限责任公司 Process for preparing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid and use for production of primovist tm
CN109705104A (en) 2019-01-28 2019-05-03 湖北天舒药业有限公司 The preparation method and applications of gadolinium system ionic contrast agent intermediate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001314763A (en) * 2000-05-10 2001-11-13 Johnson Matthey Japan Inc CARRIER FOR NOx ABSORBING AND REDUCING CATALYST AND NOx ABSORBING AND REDUCING CATALYST USING THE SAME
CN1623664A (en) * 2003-12-03 2005-06-08 浙江大学 Titanium zirconium Sosoloid and preparation process thereof
CN100531906C (en) * 2006-04-30 2009-08-26 肇庆学院 A kind of preparation method of solid superacid
CN104740655B (en) * 2015-02-13 2018-01-19 华东理工大学 One kind has NMR contrast agent of hyperhydrated constant and preparation method thereof
CN108290849B (en) * 2015-12-10 2022-03-22 伯拉考成像股份公司 Contrast agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791089A (en) * 1983-10-07 1988-12-13 Enron Chemical Corporation Zirconia-titania-silica tergels and their use as catalyst supports
CN103068790A (en) 2010-06-11 2013-04-24 拜耳知识产权有限责任公司 Process for preparing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid and use for production of primovist tm
CN109705104A (en) 2019-01-28 2019-05-03 湖北天舒药业有限公司 The preparation method and applications of gadolinium system ionic contrast agent intermediate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Valencic, M. Tetrahedron Letters, 39, 1995, 1625. *

Also Published As

Publication number Publication date
EP3835286B1 (en) 2023-01-11
ES2942312T3 (en) 2023-05-31
JP2021527621A (en) 2021-10-14
CN109851516A (en) 2019-06-07
US20210179568A1 (en) 2021-06-17
JP7128890B2 (en) 2022-08-31
WO2020154891A1 (en) 2020-08-06
KR20210045348A (en) 2021-04-26
CN109851516B (en) 2020-10-02
EP3835286A4 (en) 2022-05-11
EP3835286A1 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
US20200397924A1 (en) Preparation method of intermediate of gadolinium-based ionic contrast agent and use thereof
Randazzo et al. Halipeptins A and B: two novel potent anti-inflammatory cyclic depsipeptides from the Vanuatu marine sponge Haliclona species
CN106967083B (en) Preparation process method of gadobutrol epoxy side chain intermediate
CN108299322A (en) A method of preparing high-purity Gadobutrol
CN106187800B (en) A kind of class EDTA ligands containing adjacent two phenolic hydroxyl groups and non-gadolinium magnetic resonance contrast agent and preparation method thereof
US11618737B2 (en) Hydrolysis method for tert-butyl ester in gadolinium-based contrast agent
EP2580184A2 (en) Process for preparing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid and use for production of primovist®
CN105646446B (en) A method of purifying Egelieting
Kusukawa et al. Recognition of carboxylic acids and phosphonic acids using 1, 8-diphenylnaphthalene-based diguanidine
EP3093285B1 (en) Gadolinium complex comprising do3a-tranexamic acid conjugate
US12370271B2 (en) Gadolinium-based compound, preparation method therefor, and MRI contrast agent containing same
JPH045287A (en) Reagent for determining vitamin ds and production thereof
Huang et al. One-pot Synthesis of PEGylated Gd-based Nanoparticles as High-performance and Biocompatibility Contrast Agents for T 1-Weighted Magnetic Resonance Imaging In vivo
CN105152975B (en) Synthetic method for acetohydroxamic acid
CN111620816B (en) Propeller derivatives, preparation method, pharmaceutical composition and application thereof
EP4219510B1 (en) Novel compound and mri contrast agent comprising the same
CN111732576B (en) Bioorthogonally activated time-resolved responsive rare-earth probe and its preparation method and application
TWI651097B (en) Method for preparing contrast agent precursor
Huang et al. A Novel Synthesis of 1, 4, 7, 10-Tetraazacyclododecane by the Tandem Reaction of a Vinylsulfonium Salt
CN102209559A (en) Diagnostic and/or therapeutic agent, method for the manufacture thereof and use thereof
WO2021016339A1 (en) Modular chemical probe for detection of amino acid citrulline in physiological samples
CN109568607A (en) A kind of gadolinium Base Metal fullerene water dissolubility nitrene derivative and the preparation method and application thereof
CN103012226B (en) Preparation method of isothiocyanic acid ethyl ester
CN111116498A (en) Preparation method of homopiperazine-5-ketone hydrochloride
HUP0201634A2 (en) In vivo stain compounds and methods of use to identify dysplastic tissue

Legal Events

Date Code Title Description
AS Assignment

Owner name: HUBEI TIANSHU PHARMACEUTICAL CO., LTD, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, ZHIHUA;LIU, YUNLONG;REEL/FRAME:052551/0621

Effective date: 20200417

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCF Information on status: patent grant

Free format text: PATENTED CASE